Skip to search formSkip to main contentSkip to account menu

imatinib

Known as: Imatinibum, 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide, Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide 
An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that… 
National Institutes of Health

Related topics

Related topics

11 relations

Narrower (3)

CGP 57148GleevecSTI571
Fusion Proteins, bcr-ablImatinib mesylateMast/Stem Cell Growth Factor Receptor Kit, humanNCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Ponatinib for chronic myeloid leukemia.
The treatment of patients with chronic myeloid leukemia (CML) must be ranked as one of the great medical success stories of the… 
2012
2012
Polypharmacology in drug discovery
List of contributors. Preface. Introduction: the case for polypharmacology Andrew L. Hopkins Part A: Polypharmacology a safety… 
2010
2010
Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro
Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro 
2010
2010
Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies.
6511 Background: AP24534, an oral multiple tyrosine kinase inhibitor (TKI), is a potent pan-BCR-ABL inhibitor, including T315I. A… 
2009
2009
Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.
Abstract 3290 Poster Board III-1 [][1] There is a great variability in the degree of molecular responses achieved by chronic… 
2008
2008
Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard- dose imatinib: 2-year follow-up data from START-R
7012 Background: Resistance to imatinib is a well-recognized problem in CML-CP. Dasatinib is 325-fold more potent than imatinib… 
Highly Cited
2006
Highly Cited
2006
CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.
Intravenous infusion of autologous chronic lymphocytic leukemia (CLL) cells transduced with an adenovirus encoding CD40-ligand… 
2004
2004
Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts
Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR… 
2003
2003
Chromosomal abnormalities in Ph- cells of patients on imatinib.
The introduction of imatinib has been a major advance in the treatment of chronic myeloid leukemia (CML). Based on the results of… 
1976
1976
Urinary excretion of methaqualone-N-oxide in man.
1. Oral administration of therapeutic doses (250 mg) of methaqualone (Melsed) to adult human subjects gives rise to the urinary… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)